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to view.Insights From the Early Experience of the Society of Thoracic Surgeons/
American College of Cardiology Transcatheter Valve Therapy Registry377John S. Rumsfeld, David R. Holmes, Jr, Wendy Gattis Stough, Fred H. Edwards,
Louis B. Jacques, Michael J. MackThe Society of Thoracic Surgeons and the American College of Cardiology partnered to form the
Transcatheter Valve Therapy (TVT) Registry in close collaboration with the U.S. Food and Drug
Administration and the Center for Medicare and Medicaid Services. The goal of the TVT Registry is
to measure and improve quality of care and patient outcomes in clinical practice and to have a
pivotal role in the scientiﬁc evidence and surveillance for medical devices. A number of challenges
were faced in the early experience of the TVT Registry. Insights gained from these experiences may
help professional societies and other stakeholders plan future registries for other medical devices.CLINICAL RESEARCH
CORONARY Comparison Among Drug-Eluting Balloon, Drug-Eluting Stent, and Plain Balloon
Angioplasty for the Treatment of In-Stent Restenosis: A Network Meta-Analysis
of 11 Randomized, Controlled Trials382Joo Myung Lee, Jonghanne Park, Jeehoon Kang, Ki-Hyun Jeon, Ji-hyun Jung,
Sang Eun Lee, Jung-Kyu Han, Hack-Lyoung Kim, Han-Mo Yang, Kyung Woo Park,
Hyun-Jae Kang, Bon-Kwon Koo, Hyo-Soo KimA network meta-analysis was performed of 11 randomized, controlled trials comparing the efﬁcacy
and safety of drug-eluting balloons (DEB), drug-eluting stents (DES), and plain old balloon
angioplasty (POBA) for the treatment of in-stent restenosis (ISR). The risk of target lesion
revascularization (TLR) was markedly lower in the DEB or DES group than in the POBA group. In a
comparison of DEB and DES, the risk of TLR was similar. The risk of myocardial infarction (MI) was
slightly higher after treatment with DES compared with DEB or POBA, although these results were
insigniﬁcant. Local drug delivery by DEB or DES for ISR lesions was markedly better than POBA in
preventing TLR, but not for MI or mortality. Of the 2 different strategies of drug delivery for ISR
lesions, treatment with DEB showed a trend of a lower occurrence of MI than did treatment with DES.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
Do We Know the Best Treatment for In-Stent Restenosis Via Network Meta-Analysis
(NMA)? Simple Methods Any Interventionalist Can Use to Assess NMA Quality and
a Call for Better NMA Presentation395Stephen G. EllisCONTINUED ON PAGE A-29
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MARCH 2015 VOLUME 8, NUMBER 3The Impact of Downstream Coronary Stenosis on Fractional Flow Reserve Assessment
of Intermediate Left Main Coronary Artery Disease: Human Validation398William F. Fearon, Andy S. Yong, Guy Lenders, Gabor G. Toth, Catherine Dao,
David V. Daniels, Nico H.J. Pijls, Bernard De BruyneIn theory, fractional ﬂow reserve (FFR) across an intermediate left main coronary artery (LMCA)
stenosis will be affected by downstream disease, even if the pressure wire is positioned in the
nondiseased downstream vessel. An intermediate stenosis was artiﬁcially created in the LMCA of
25 patients. A variable degree of stenosis was created in the left anterior descending or left
circumﬂex, whereas FFR was measured in the other vessel. In most cases, downstream disease did
not have a clinically signiﬁcant impact on the assessment of FFR across an intermediate LMCA
stenosis with the pressure wire positioned in the nondiseased vessel.
Thrombotic Complications Associated With Early and Late Nonadherence
to Dual Antiplatelet Therapy404Donald E. Cutlip, Dean J. Kereiakes, Laura Mauri, Robert Stoler, Harold L. Dauerman,
for the EDUCATE InvestigatorsIn a nonrandomized registry with limited exclusions, 2,265 patients were enrolled after receiving an
Endeavor zotarolimus-eluting stent and prescribed 12 months of dual antiplatelet therapy (DAPT).
Any nonadherence (ANA) to dual antiplatelet therapy occurred in 208 patients (9.6%) within
6 months and 378 patients (18.5%) within 1 year. ANA within 6 months was associated with
increased risk for death or myocardial infarction (7.6% vs. 3.0%, p < 0.001) compared with full
adherence. Among patients who had full adherence for 6 months, subsequent ANA was not
associated with increased risk for death or myocardial infarction.n EDITORIAL COMMENT
Noncompliance and Cessation of Dual Antiplatelet Therapy After Coronary Stenting:
Looking at the Speck Rather Than Noticing the Log?411Giuseppe Biondi-Zoccai, Giacomo Frati, Antonio Abbate
Novel Approaches for Preventing or Limiting Events (Naples) III Trial:
Randomized Comparison of Bivalirudin Versus Unfractionated Heparin in Patients at
Increased Risk of Bleeding Undergoing Transfemoral Elective Coronary Stenting414Carlo Briguori, Gabriella Visconti, Amelia Focaccio, Michael Donahue, Bruno Golia,
Lucio Selvetella, Bruno RicciardelliConsecutive biomarker negative patients at increased bleeding risk undergoing transfemoral
percutaneous coronary intervention were randomized to unfractionated heparin (UFH) (UFH group;
n ¼ 419) or bivalirudin (bivalirudin group; n ¼ 418). The rate of in-hospital major bleeding
(primary endpoint) endpoint occurred in 11 patients (2.6%) in the UFH group versus 14 patients
(3.3%) in the bivalirudin group (odds ratio: 0.78; 95% conﬁdence interval: 0.35 to 1.72;
p ¼ 0.54). The results of this randomized study, carried out at a single institution, suggest that
there is no difference in major bleeding rate between bivalirudin and UFH in increased-risk
patients undergoing transfemoral percutaneous coronary intervention.
SEE ADDITIONAL CONTENT ONLINECONTINUED ON PAGE A-30
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MARCH 2015 VOLUME 8, NUMBER 3Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin: Insights
From the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel
Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI])424Harvey D. White, Deepak L. Bhatt, C. Michael Gibson, Christian W. Hamm,
Kenneth W. Mahaffey, Matthew J. Price, Ph. Gabriel Steg, Gregg W. Stone,
Bernardo Cortese, Michael Wilensky, Efthymios N. Deliargyris, Tiepu Liu,
Jayne Prats, Robert A. HarringtonOutcomes of cangrelor among patients in the CHAMPION PHOENIX (A Clinical Trial Comparing
Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary
Intervention [PCI]) who underwent percutaneous coronary intervention with bivalirudin were
examined; 2,059 patients (18.8%) received bivalirudin, with 1,014 patients randomized to
cangrelor and 1,045 randomized to clopidogrel. At 48 h, the primary endpoint of death,
myocardial infarction, ischemia-driven revascularization, or stent thrombosis was lower with
cangrelor versus clopidogrel (48 [4.7%] vs. 70 [6.7%]; odds ratio: 0.68, p ¼ 0.047). Cangrelor
was associated with a trend for less stent thrombosis (7 [0.7%] vs. 15 [1.4%]; odds ratio: 0.48,
p ¼ 0.10). GUSTO (Global Use of Strategies to Open Occluded Arteries) severe bleeding was
similar in both arms. Cangrelor may offer an attractive beneﬁt risk proﬁle when used with bivalirudin.n EDITORIAL COMMENT
The Arranged Marriage of Cangrelor and Bivalirudin 434
Gilles Montalescot, Gérard Helft
Blood Transfusion After Percutaneous Coronary Intervention and Risk of Subsequent
Adverse Outcomes: A Systematic Review and Meta-Analysis436Chun Shing Kwok, Matthew W. Sherwood, Sarah M. Watson, Samina B. Nasir,
Matt Sperrin, Jim Nolan, Tim Kinnaird, Songsak Kiatchoosakun, Peter F. Ludman,
Mark A. de Belder, Sunil V. Rao, Mamas A. MamasThis systematic review and meta-analysis aims to deﬁne the prevalence and prognostic impact
of blood transfusions in contemporary percutaneous coronary intervention practice. A search
of EMBASE and MEDLINE was conducted, and meta-analysis was performed on 19 studies
(2,258,711 patients, 54,000+ transfusion events, prevalence of blood transfusion 2.3%). Mortality
rates were 12.6% in patients who received a blood transfusion and 1.2% in the remaining patients,
and the respective major adverse cardiac event rates were 17.4% and 3.1%. Blood transfusion was
independently associated with an increase in mortality (odds ratio [OR]: 3.02, 95% conﬁdence
interval [CI]: 2.16 to 4.21) and major adverse cardiac events (OR: 3.15, 95% CI: 2.59 to 3.82). In
conclusion, clinicians should use bleeding-avoidance strategies and avoid liberal transfusion
practices.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
Real Dilemmas Regarding Blood Transfusion 447
George Dangas, Jaya ChandrasekharCONTINUED ON PAGE A-31
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MARCH 2015 VOLUME 8, NUMBER 3STRUCTURAL Persistence of Iatrogenic Atrial Septal Defect After Interventional Mitral Valve Repair
With the MitraClip System: A Note of Caution450Robert Schueler, Can Öztürk, Jan Arne Wedekind, Nikos Werner, Florian Stöckigt,
Fritz Mellert, Georg Nickenig, Christoph HammerstinglThe authors investigated persistence rates of iatrogenic atrial septal defect (iASD) after MitraClip
procedure and clinical outcome after 6 months. Transesophageal echocardiography after follow-up
showed persistent iASD in 50% of cases. Patients with iASD were not statistically different from
patients without ASD concerning baseline characteristics. After follow-up patients with iASD were
more symptomatic, showed higher levels of N-terminal pro-brain-natriuretic-peptide and less
improvement in 6-min walking distances. Patients with iASD had higher death rates during 6
months. Cox regression analysis showed only persistence of iASD to be associated with 6-month
survival.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
The Transseptal Conundrum 460
Peter C. Block
Incidence and Severity of Paravalvular Aortic Regurgitation With Multidetector
Computed Tomography Nominal Area Oversizing or Undersizing After Transcatheter
Heart Valve Replacement With the Sapien 3: A Comparison With the Sapien XT462Tae-Hyun Yang, John G. Webb, Philipp Blanke, Danny Dvir, Nicolaj C. Hansson,
Bjarne L. Nørgaard, Christopher R. Thompson, Martyn Thomas, Olaf Wendler,
Alec Vahanian, Dominique Himbert, Susheel K. Kodali, Rebecca T. Hahn,
Vinod H. Thourani, Gerhard Schymik, Bruce Precious, Adam Berger, David A. Wood,
Philippe Pibarot, Josep Rodés-Cabau, Wael A. Jaber, Martin B. Leon, Thomas Walther,
Jonathon LeipsicA total of 61 patients undergoing transcatheter aortic valve replacement with the Sapien 3
transcatheter heart valve (THV) were compared with 92 patients undergoing transcatheter aortic
valve replacement with the Sapien XT THV. Mild or greater paravalvular aortic regurgitation (PAR)
was present in 19.7% of patients with Sapien 3 and in 54.3% of patients with Sapien XT
(p < 0.01). In the Sapien 3 group, a multidetector computed tomography (MDCT) area oversizing
percentage of #4.17% was identiﬁed as the optimal cutoff value to predict mild or greater PAR.
The Sapien 3 THV, compared with the Sapien XT THV, displays signiﬁcantly lower rates of PAR. A
lesser degree of MDCT area oversizing may be employed for this new balloon-expandable prosthesis.CONTINUED ON PAGE A-32
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MARCH 2015 VOLUME 8, NUMBER 3PERIPHERAL Outcomes of Spot Stenting Versus Long Stenting After Intentional Subintimal Approach
for Long Chronic Total Occlusions of the Femoropopliteal Artery472Sung-Jin Hong, Young-Guk Ko, Dong-Ho Shin, Jung-Sun Kim, Byeong-Keuk Kim,
Donghoon Choi, Myeong-Ki Hong, Yangsoo JangThis study compared the outcomes of spot stenting versus long stenting after subintimal approach
for long femoropopliteal occlusions. The incidence or type of stent fracture and restenosis pattern
did not differ between groups. However, the primary patency and the freedom of target lesion
revascularization were signiﬁcantly lower in the long stenting group. Compared with spot stenting,
long stenting, particularly extending to the P2 or P3 popliteal artery segment, had a 7.5-fold
increased risk of restenosis. Thus, full coverage with stents extending to the popliteal artery after
subintimal approach was associated with poor outcomes in long femoropopliteal occlusions.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
Focal Stenting Versus “Metal Jacket” for Long Subintimal Recanalization
of the Femoropopliteal Artery481Khusrow NiaziTRANSLATIONAL Transatrial Intrapericardial Tricuspid Annuloplasty 483
Toby Rogers, Kanishka Ratnayaka, Merdim Sonmez, Dominique N. Franson,
William H. Schenke, Jonathan R. Mazal, Ozgur Kocaturk, Marcus Y. Chen,
Anthony Z. Faranesh, Robert J. LedermanTransatrial intrapericardial tricuspid annuloplasty (TRAIPTA) modiﬁes the geometry of the tricuspid
annulus to reduce functional tricuspid regurgitation (TR). TRAIPTA was performed in 16 swine,
including 4 with functional TR, via a transatrial puncture into the pericardium. In 9 naive animals,
tricuspid septal-lateral and anteroposterior dimensions, the annular area and perimeter,
were reduced by 49%, 31%, 59%, and 24% (p < 0.001) respectively. Tricuspid leaﬂet
coaptation length was increased by 53% (p < 0.001). These geometric changes were maintained
at follow-up (mean, 9.7 days). Small effusions, observed post-procedure, resolved completely at
follow-up. In 4 animals with functional TR, severity of regurgitation by intracardiac
echocardiography was reduced.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
Functional Tricuspid Regurgitation: Percutaneous Therapies Needed 492
Jason H. RogersCONTINUED ON PAGE A-33
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MARCH 2015 VOLUME 8, NUMBER 3IMAGES IN
INTERVENTIONPercutaneous Closure of a Large Ascending Aorta Pseudoaneurysm Due
to Mediastinitis Using an Amplatzer Occluder Device495Manolis Vavuranakis, Konstantinos Kalogeras, Carmen Moldovan, Sophia Vaina,
Dimitrios Vrachatis, Maria Kariori, Evelina Mpei, Dimitrios Tousoulis,
Christodoulos StefanadisSEE ADDITIONAL CONTENT ONLINESevere Valve Deformation Following Cardiopulmonary Resuscitation in a Patient
With a Transcatheter Aortic Valve498Creighton W. Don, James M. McCabe, Corinne L. Fligner
n ONLINE FEATURE Longitudinal Elongation, Axial Compression, and Effects on
Strut Geometry of Bioresorbable Vascular Scaffolds: Insights From 2- and
3-Dimensional Optical Coherence Tomography Imaginge35Yohei Ohno, Guilherme F. Attizzani, Davide Capodanno, Claudia I. Tamburino,
Giovanni Longo, Yusuke Fujino, Piera Capranzano, Corrado Tamburino
n ONLINE FEATURE Embolization of Cardiac Arteriovenous Malformation
With Onyxe39Vakhtang Tchantchaleishvili, Victor Becerra-Gonzales, Genaro Fernandez,
Hanna Z. Mieszczanska, Babak S. Jahromi, Christopher J. Cove
n ONLINE FEATURE New-Onset Coronary Aneurism and Late-Acquired Incomplete
Scaffold Apposition After Full Polymer Jacket of a Chronic Total Occlusion With
Bioresorbable Scaffoldse41Giuseppe Gargiulo, Andrea Mangiameli, Francesco Granata, Yohei Ohno, Alberto Chisari,
Davide Capodanno, Corrado Tamburino, Alessio La Manna
n ONLINE FEATURE Extravasation From an Accessory Renal Artery:
A Critical Complication Associated With Percutaneous Coronary Interventione45Nobuaki Kobayashi, Noritake Hata, Tomoyuki Kuwako, Wataru Shimizu
n ONLINE FEATURE A Potential Procedural Complication 2 Years After Percutaneous
Coronary Intervention to Treat Left Anterior Descending Artery Lesions With the
T-Stenting and the Small Protrusion Techniquee49Kenichi Karube, Yusuke Fujino, Toru Naganuma, Satoko Tahara, Shotaro Nakamura,
Sunao Nakamura, Antonio Colombo
n ONLINE FEATURE Fate of Side-Branch Jailing and a Malapposed Platinum Marker
After Resorption of an Everolimus-Eluting Bioresorbable Vascular Scaffold:
Serial Optical Coherence Tomography Observationse53Antonios Karanasos, Hector M. Garcia-Garcia, Robert-Jan van Geuns, Evelyn Regar
n ONLINE FEATURE THESE ARTICLES DO NOT APPEAR IN THE PRINTED ISSUE.
THEY ARE AVAILABLE IN THE ONLINE VERSION OF THIS ISSUE.CONTINUED ON PAGE A-34
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